Cardiovascular
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Access global pharma market insights on cardiovascular drug development, clinical trials, regulatory approvals, and M&A activity. Stay ahead.
Showing 1–12 of 20 articles
Quick answer
NovaPharmaNews Cardiovascular hub for FDA covers 20 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors
Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
ISPOR 2026: Top Cardiology Innovations & Research Highlights
ISPOR 2026: Cardiology Advances in Cost-Effectiveness Research
Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in Pivotal Aortic Valve Trial
Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection
Mounjaro FDA Approval Obesity: Eli Lilly's Tirzepatide Awaits
AOP Health US Treats First Patient with Rapiblyk (Landiolol) in United States at Valley Hospital
SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling
Berlin Heals Reports Positive First-in-Human Results for Less Invasive Heart Failure Device in CMIC-III Study
Nectero Therapeutics Reports Positive Two-Year Safety Data for EAST System in Abdominal Aortic Aneurysm Trial
Efemoral Medical's Bioresorbable Scaffold Achieves 97% Patency Rate in Peripheral Artery Disease Trial
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.